
    
      To demonstrate non-inferiority of treatment with atazanavir/ritonavir (ATV/r) 200/100 mg once
      daily (OD) compared to the control group (ATV/r 300/100 mg OD) in regards to the proportion
      of virologic responders (plasma HIV RNA < 200 copies/mL) at 48 weeks in ARV-experienced HIV-1
      infected subjects.
    
  